Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment

Clinical trial NCT07638722 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07638722
Sponsor: SWOG Cancer Research Network
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Recurrent Nodal Marginal Zone Lymphoma Recurrent Splenic Marginal Zone Lymphoma Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Refractory Nodal Marginal Zone Lymphoma Refractory Splenic Marginal Zone Lymphoma

Start date: 2026-10-03
Primary completion: 2034-04-03
Enrollment: 138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.